| 1 | Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice? | 4.0 | 1 | Citations (PDF) |
| 2 | Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes | 2.1 | 3 | Citations (PDF) |
| 3 | Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy | 6.4 | 0 | Citations (PDF) |
| 4 | ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors | 3.0 | 0 | Citations (PDF) |
| 5 | Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study | 3.0 | 3 | Citations (PDF) |
| 6 | Differences in Breast Cancer Subtypes among Racial/Ethnic Groups | 4.0 | 0 | Citations (PDF) |
| 7 | Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer | 6.9 | 0 | Citations (PDF) |
| 8 | Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer | 5.5 | 17 | Citations (PDF) |
| 9 | Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines | 3.6 | 1 | Citations (PDF) |
| 10 | Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients | 4.0 | 7 | Citations (PDF) |
| 11 | Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer | 3.0 | 2 | Citations (PDF) |
| 12 | Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial | 4.0 | 9 | Citations (PDF) |
| 13 | Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment | 5.1 | 15 | Citations (PDF) |
| 14 | Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC | 6.8 | 6 | Citations (PDF) |
| 15 | A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer | 3.7 | 4 | Citations (PDF) |
| 16 | Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy | 2.1 | 16 | Citations (PDF) |
| 17 | Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer | 4.0 | 10 | Citations (PDF) |
| 18 | Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling | 14.1 | 9 | Citations (PDF) |
| 19 | NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis | 5.1 | 29 | Citations (PDF) |
| 20 | Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer | 6.4 | 17 | Citations (PDF) |
| 21 | Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape | 3.9 | 3 | Citations (PDF) |
| 22 | Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement | 1.7 | 3 | Citations (PDF) |
| 23 | An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody–Drug Conjugates | 1.7 | 20 | Citations (PDF) |
| 24 | A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System | 4.0 | 27 | Citations (PDF) |
| 25 | EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer | 11.3 | 28 | Citations (PDF) |
| 26 | Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy | 1.9 | 2 | Citations (PDF) |
| 27 | Update on systemic treatment for newly diagnosed inflammatory breast cancer | 10.9 | 25 | Citations (PDF) |
| 28 | Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis | 1.7 | 20 | Citations (PDF) |
| 29 | Body composition and breast cancer risk and treatment: mechanisms and impact | 2.5 | 58 | Citations (PDF) |
| 30 | Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer | 4.5 | 45 | Citations (PDF) |
| 31 | Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase | 3.4 | 19 | Citations (PDF) |
| 32 | The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer | 1.7 | 16 | Citations (PDF) |
| 33 | The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy | 4.0 | 10 | Citations (PDF) |
| 34 | Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope | 2.7 | 12 | Citations (PDF) |
| 35 | Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review | 2.5 | 4 | Citations (PDF) |
| 36 | Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers | 9.9 | 13 | Citations (PDF) |
| 37 | Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer | 4.0 | 12 | Citations (PDF) |
| 38 | PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening | 3.6 | 10 | Citations (PDF) |
| 39 | A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores | 2.5 | 7 | Citations (PDF) |
| 40 | Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance | 14.1 | 151 | Citations (PDF) |
| 41 | Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer | 1.7 | 8 | Citations (PDF) |
| 42 | Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression | 2.5 | 4 | Citations (PDF) |
| 43 | Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer | 6.4 | 41 | Citations (PDF) |
| 44 | Inflammatory Breast Cancer at the Extremes of Age | 1.7 | 5 | Citations (PDF) |
| 45 | Inflammatory breast cancer appearance at presentation is associated with overall survival | 2.8 | 12 | Citations (PDF) |
| 46 | Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion | 4.2 | 23 | Citations (PDF) |
| 47 | A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer | 4.0 | 24 | Citations (PDF) |
| 48 | Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer | 0.6 | 10 | Citations (PDF) |
| 49 | Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors | 5.6 | 28 | Citations (PDF) |
| 50 | ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells | 3.6 | 10 | Citations (PDF) |
| 51 | A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer | 3.7 | 13 | Citations (PDF) |
| 52 | Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases | 1.6 | 2 | Citations (PDF) |
| 53 | “Why and What” for the optimal management of inflammatory breast cancer | 1.4 | 0 | Citations (PDF) |
| 54 | Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer | 2.8 | 18 | Citations (PDF) |
| 55 | NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers | 4.2 | 26 | Citations (PDF) |
| 56 | Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis | 5.1 | 15 | Citations (PDF) |
| 57 | The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer | 2.5 | 2 | Citations (PDF) |
| 58 | Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? | 1.7 | 13 | Citations (PDF) |
| 59 | Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer | 4.0 | 2 | Citations (PDF) |
| 60 | Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters | 2.4 | 14 | Citations (PDF) |
| 61 | Targeting Signaling Pathways in Inflammatory Breast Cancer | 4.0 | 22 | Citations (PDF) |
| 62 | NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer | 4.0 | 21 | Citations (PDF) |
| 63 | Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic | 2.4 | 5 | Citations (PDF) |
| 64 | Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC | 3.0 | 5 | Citations (PDF) |
| 65 | The CD151‐midkine pathway regulates the immune microenvironment in inflammatory breast cancer | 5.2 | 15 | Citations (PDF) |
| 66 | Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin | 4.8 | 5 | Citations (PDF) |
| 67 | Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab | 3.6 | 2 | Citations (PDF) |
| 68 | Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis | 0.6 | 45 | Citations (PDF) |
| 69 | Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research | 2.5 | 19 | Citations (PDF) |
| 70 | JNK Signaling in Stem Cell Self-Renewal and Differentiation | 4.5 | 62 | Citations (PDF) |
| 71 | EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy | 2.5 | 25 | Citations (PDF) |
| 72 | Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes | 0.9 | 22 | Citations (PDF) |
| 73 | Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity | 2.5 | 14 | Citations (PDF) |
| 74 | Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer | 3.7 | 35 | Citations (PDF) |
| 75 | Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer | 3.8 | 44 | Citations (PDF) |
| 76 | Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium | 2.7 | 20 | Citations (PDF) |
| 77 | Patient reported outcomes can improve performance status assessment: a pilot study | 2.6 | 24 | Citations (PDF) |
| 78 | Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype | 2.5 | 18 | Citations (PDF) |
| 79 | Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach | 2.6 | 10 | Citations (PDF) |
| 80 | The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer | 2.7 | 4 | Citations (PDF) |
| 81 | A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment | 5.7 | 26 | Citations (PDF) |
| 82 | Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer | 2.5 | 20 | Citations (PDF) |
| 83 | Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer | 3.7 | 76 | Citations (PDF) |
| 84 | Imaging features of triple-negative breast cancers according to androgen receptor status | 3.1 | 12 | Citations (PDF) |
| 85 | Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer | 2.5 | 20 | Citations (PDF) |
| 86 | Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer | 1.7 | 9 | Citations (PDF) |
| 87 | Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model | 3.6 | 7 | Citations (PDF) |
| 88 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study | 2.6 | 29 | Citations (PDF) |
| 89 | Bone Metastasis of Breast Cancer | 0.0 | 97 | Citations (PDF) |
| 90 | Factors associated with improved outcomes for metastatic inflammatory breast cancer patients | 2.5 | 14 | Citations (PDF) |
| 91 | Development of CNS metastases and survival in patients with inflammatory breast cancer | 4.4 | 11 | Citations (PDF) |
| 92 | Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications | 0.6 | 22 | Citations (PDF) |
| 93 | Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue | 4.4 | 0 | Citations (PDF) |
| 94 | Inflammatory breast cancer biology: the tumour microenvironment is key | 24.2 | 240 | Citations (PDF) |
| 95 | Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer | 2.4 | 20 | Citations (PDF) |
| 96 | The Emerging Impact of Social Media on Cancer Patient Education in Japan | 3.6 | 2 | Citations (PDF) |
| 97 | Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer | 2.4 | 30 | Citations (PDF) |
| 98 | <i>BRCA</i> mutations in women with inflammatory breast cancer | 4.4 | 13 | Citations (PDF) |
| 99 | Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer | 3.3 | 3 | Citations (PDF) |
| 100 | Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer | 2.1 | 48 | Citations (PDF) |
| 101 | ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK–AKT–mTOR Signaling Pathway | 1.7 | 71 | Citations (PDF) |
| 102 | Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center | 2.5 | 17 | Citations (PDF) |
| 103 | Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype | 2.5 | 36 | Citations (PDF) |
| 104 | Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis | 2.7 | 20 | Citations (PDF) |
| 105 | Inflammatory Breast Cancer | 2.2 | 74 | Citations (PDF) |
| 106 | Low-dimensional dynamical characterization of human performance of cancer patients using motion data | 1.4 | 5 | Citations (PDF) |
| 107 | CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer | 3.7 | 31 | Citations (PDF) |
| 108 | Survivorship and Advocacy in Inflammatory Breast Cancer | 2.7 | 5 | Citations (PDF) |
| 109 | International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference | 2.7 | 90 | Citations (PDF) |
| 110 | Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience | 2.4 | 10 | Citations (PDF) |
| 111 | Reply to ‘A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18’ | 2.6 | 2 | Citations (PDF) |
| 112 | Clinically relevant inflammatory breast cancer patient-derived xenograft–derived ex vivo model for evaluation of tumor-specific therapies | 2.5 | 16 | Citations (PDF) |
| 113 | Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole | 3.8 | 4 | Citations (PDF) |
| 114 | Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer | 13.6 | 61 | Citations (PDF) |
| 115 | Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux | 6.6 | 29 | Citations (PDF) |
| 116 | Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes | 2.5 | 11 | Citations (PDF) |
| 117 | Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer | 1.7 | 8 | Citations (PDF) |
| 118 | Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy | 5.7 | 17 | Citations (PDF) |
| 119 | Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer | 4.1 | 41 | Citations (PDF) |
| 120 | Identification of frequent somatic mutations in inflammatory breast cancer | 2.5 | 30 | Citations (PDF) |
| 121 | Outcomes in patients with early‐stage breast cancer who underwent a 21‐gene expression assay | 4.4 | 19 | Citations (PDF) |
| 122 | Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression | 2.5 | 33 | Citations (PDF) |
| 123 | Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer | 6.4 | 35 | Citations (PDF) |
| 124 | Novel therapeutic strategies in the treatment of triple-negative breast cancer | 3.8 | 57 | Citations (PDF) |
| 125 | Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system | 21.9 | 77 | Citations (PDF) |
| 126 | Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer | 13.6 | 166 | Citations (PDF) |
| 127 | Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer | 4.4 | 10 | Citations (PDF) |
| 128 | Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy’’ | 5.7 | 0 | Citations (PDF) |
| 129 | Somatic mutations reveal asymmetric cellular dynamics in the early human embryo | 40.1 | 192 | Citations (PDF) |
| 130 | Association between weight gain during adjuvant chemotherapy for early‐stage breast cancer and survival outcomes | 2.8 | 28 | Citations (PDF) |
| 131 | Thrombocytosis as a prognostic factor in inflammatory breast cancer | 2.5 | 18 | Citations (PDF) |
| 132 | Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery | 1.7 | 33 | Citations (PDF) |
| 133 | Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer | 5.0 | 47 | Citations (PDF) |
| 134 | In response to “outcomes of patients with inflammatory breast cancer treated by breast conserving surgery”: the argument against breast conservation and sentinel lymph node biopsy in IBC | 2.5 | 4 | Citations (PDF) |
| 135 | Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10<sup>th</sup> Anniversary Conference | 2.7 | 13 | Citations (PDF) |
| 136 | Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation | 2.7 | 15 | Citations (PDF) |
| 137 | Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors | 2.5 | 6 | Citations (PDF) |
| 138 | Androgen receptor expression on circulating tumor cells in metastatic breast cancer | 2.5 | 19 | Citations (PDF) |
| 139 | Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival | 2.7 | 4 | Citations (PDF) |
| 140 | Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status | 2.7 | 8 | Citations (PDF) |
| 141 | MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer | 2.1 | 7 | Citations (PDF) |
| 142 | Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells | 5.1 | 27 | Citations (PDF) |
| 143 | Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer | 1.7 | 42 | Citations (PDF) |
| 144 | Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer | 1.7 | 39 | Citations (PDF) |
| 145 | EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer | 1.7 | 37 | Citations (PDF) |
| 146 | Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes | 1.7 | 14 | Citations (PDF) |
| 147 | A target of potential RELAvance in inflammatory breast cancer | 1.7 | 0 | Citations (PDF) |
| 148 | Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel | 2.7 | 8 | Citations (PDF) |
| 149 | High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer | 3.6 | 19 | Citations (PDF) |
| 150 | miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer | 5.1 | 63 | Citations (PDF) |
| 151 | Neoadjuvant nab-paclitaxel in the treatment of breast cancer | 2.5 | 19 | Citations (PDF) |
| 152 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | 40.1 | 1,561 | Citations (PDF) |
| 153 | Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy | 2.5 | 13 | Citations (PDF) |
| 154 | Impact of clinical trial on survival outcomes | 2.5 | 4 | Citations (PDF) |
| 155 | Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer | 2.9 | 20 | Citations (PDF) |
| 156 | Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes | 7.7 | 30 | Citations (PDF) |
| 157 | Epidemiological risk factors associated with inflammatory breast cancer subtypes | 1.8 | 40 | Citations (PDF) |
| 158 | MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer | 5.0 | 34 | Citations (PDF) |
| 159 | MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer | 0.7 | 24 | Citations (PDF) |
| 160 | Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models | 1.7 | 81 | Citations (PDF) |
| 161 | Clinical outcomes based on multigene profiling in metastatic breast cancer patients | 1.7 | 22 | Citations (PDF) |
| 162 | MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study | 1.7 | 36 | Citations (PDF) |
| 163 | Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism | 1.7 | 56 | Citations (PDF) |
| 164 | Inflammatory and Locally Advanced Breast Cancer 2016, , 411-435 | | 0 | Citations (PDF) |
| 165 | Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy | 4.4 | 38 | Citations (PDF) |
| 166 | Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy | 1.4 | 28 | Citations (PDF) |
| 167 | Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer | 2.7 | 17 | Citations (PDF) |
| 168 | Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer | 2.7 | 18 | Citations (PDF) |
| 169 | Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? | 1.7 | 93 | Citations (PDF) |
| 170 | Disulfiram (DSF) acts as a copper ionophore to induce copper‐dependent oxidative stress and mediate anti‐tumor efficacy in inflammatory breast cancer | 4.2 | 185 | Citations (PDF) |
| 171 | Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future | 1.6 | 9 | Citations (PDF) |
| 172 | Circulating tumor cells in newly diagnosed inflammatory breast cancer | 5.0 | 36 | Citations (PDF) |
| 173 | Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer | 2.4 | 10 | Citations (PDF) |
| 174 | Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis | 2.5 | 71 | Citations (PDF) |
| 175 | High-Density and Very-Low-Density Lipoprotein Have Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to Radiation in Inflammatory Breast Cancer | 0.7 | 33 | Citations (PDF) |
| 176 | Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model | 5.0 | 50 | Citations (PDF) |
| 177 | Challenging a Traditional Paradigm | 2.0 | 21 | Citations (PDF) |
| 178 | Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer | 13.6 | 73 | Citations (PDF) |
| 179 | Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer | 5.1 | 24 | Citations (PDF) |
| 180 | MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model | 1.7 | 64 | Citations (PDF) |
| 181 | Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing | 0.6 | 29 | Citations (PDF) |
| 182 | Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases | 1.7 | 18 | Citations (PDF) |
| 183 | Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a | 2.5 | 53 | Citations (PDF) |
| 184 | Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer | 8.5 | 10 | Citations (PDF) |
| 185 | Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers | 2.4 | 6 | Citations (PDF) |
| 186 | Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells | 2.5 | 87 | Citations (PDF) |
| 187 | Challenges and perspective of drug repurposing strategies in early phase clinical trials | 1.6 | 41 | Citations (PDF) |
| 188 | Functional consequence of the<i>MET-T</i>1010I polymorphism in breast cancer | 1.7 | 37 | Citations (PDF) |
| 189 | High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer | 2.5 | 76 | Citations (PDF) |
| 190 | cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer | 2.7 | 42 | Citations (PDF) |
| 191 | Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination | 5.0 | 91 | Citations (PDF) |
| 192 | Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database | 17.1 | 111 | Citations (PDF) |
| 193 | Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer | 4.4 | 59 | Citations (PDF) |
| 194 | Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer | 6.4 | 29 | Citations (PDF) |
| 195 | Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer | 3.6 | 13 | Citations (PDF) |
| 196 | Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining | 2.4 | 16 | Citations (PDF) |
| 197 | Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation | 3.6 | 70 | Citations (PDF) |
| 198 | The Role of Inflammation in Inflammatory Breast Cancer | 0.0 | 48 | Citations (PDF) |
| 199 | EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer | 11.5 | 24 | Citations (PDF) |
| 200 | A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression | 2.5 | 41 | Citations (PDF) |
| 201 | Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation | 1.7 | 20 | Citations (PDF) |
| 202 | Expression of androgen receptor in inflammatory breast cancer and its clinical relevance | 4.4 | 8 | Citations (PDF) |
| 203 | Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death | 6.4 | 40 | Citations (PDF) |
| 204 | 18F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy | 5.4 | 18 | Citations (PDF) |
| 205 | TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase | 0.6 | 70 | Citations (PDF) |
| 206 | Latest biopsy approach for suspected metastases in patients with breast cancer | 25.3 | 23 | Citations (PDF) |
| 207 | Breast Cancer Biomarkers: Utility in Clinical Practice | 0.9 | 17 | Citations (PDF) |
| 208 | A Comparison of Epidemiology, Biology, and Prognosis of Inflammatory Breast Cancer in Japanese and US Populations | 2.4 | 11 | Citations (PDF) |
| 209 | A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer | 2.4 | 34 | Citations (PDF) |
| 210 | Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers | 5.0 | 48 | Citations (PDF) |
| 211 | Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets | 6.4 | 120 | Citations (PDF) |
| 212 | Genomic and expression analysis of microdissected inflammatory breast cancer | 2.5 | 47 | Citations (PDF) |
| 213 | Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP | 1.7 | 14 | Citations (PDF) |
| 214 | Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes | 6.4 | 570 | Citations (PDF) |
| 215 | Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation | 2.7 | 3 | Citations (PDF) |
| 216 | Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient | 2.7 | 4 | Citations (PDF) |
| 217 | The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer | 2.5 | 43 | Citations (PDF) |
| 218 | Bone Metastasis of Breast Cancer 2013, , 189-209 | | 0 | Citations (PDF) |
| 219 | Signaling Pathways in Inflammatory Breast Cancer 2012, , 151-160 | | 0 | Citations (PDF) |
| 220 | Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry | 17.1 | 228 | Citations (PDF) |
| 221 | Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer | 1.7 | 183 | Citations (PDF) |
| 222 | Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center | 1.6 | 16 | Citations (PDF) |
| 223 | Metastasis in the Breast Mimicking Inflammatory Breast Cancer | 17.1 | 6 | Citations (PDF) |
| 224 | Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients | 3.6 | 24 | Citations (PDF) |
| 225 | MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15–Dependent Manner in a Mouse Xenograft Model | 1.7 | 21 | Citations (PDF) |
| 226 | Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors | 17.1 | 346 | Citations (PDF) |
| 227 | Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation | 2.7 | 59 | Citations (PDF) |
| 228 | Inflammatory Breast Cancer: What We Know and What We Need to Learn | 3.6 | 124 | Citations (PDF) |
| 229 | Role of epidermal growth factor receptor in breast cancer | 2.5 | 562 | Citations (PDF) |
| 230 | Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer | 2.4 | 89 | Citations (PDF) |
| 231 | Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs | 0.7 | 42 | Citations (PDF) |
| 232 | Microfluidics separation reveals the stem-cell–like deformability of tumor-initiating cells | 7.7 | 181 | Citations (PDF) |
| 233 | Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β‐Catenin Signaling | 3.3 | 93 | Citations (PDF) |
| 234 | Bone Metastases 2012, , 591-609 | | 2 | Citations (PDF) |
| 235 | Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone‐only metastases | 4.4 | 17 | Citations (PDF) |
| 236 | Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer | 2.5 | 22 | Citations (PDF) |
| 237 | Systemic and Targeted Therapy 2012, , 85-99 | | 0 | Citations (PDF) |
| 238 | Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study 2012, , 225-242 | | 0 | Citations (PDF) |
| 239 | High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer 2012, , 127-138 | | 0 | Citations (PDF) |
| 240 | Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment | 5.0 | 181 | Citations (PDF) |
| 241 | Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt | 2.7 | 23 | Citations (PDF) |
| 242 | Targeting EGFR in Triple Negative Breast Cancer | 2.7 | 126 | Citations (PDF) |
| 243 | Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27 | 1.6 | 19 | Citations (PDF) |
| 244 | Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series | 2.4 | 9 | Citations (PDF) |
| 245 | Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early | 4.4 | 118 | Citations (PDF) |
| 246 | Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome | 4.4 | 59 | Citations (PDF) |
| 247 | Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells | 4.5 | 97 | Citations (PDF) |
| 248 | Initial Staging Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Breast Cancer | 3.6 | 16 | Citations (PDF) |
| 249 | Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer | 3.6 | 9 | Citations (PDF) |
| 250 | A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer | 13.7 | 497 | Citations (PDF) |
| 251 | High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials | 17.1 | 83 | Citations (PDF) |
| 252 | Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer | 3.6 | 82 | Citations (PDF) |
| 253 | High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials | 17.1 | 62 | Citations (PDF) |
| 254 | Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis | 3.6 | 52 | Citations (PDF) |
| 255 | FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer | 3.6 | 77 | Citations (PDF) |
| 256 | Improvement of survival and prospect of cure in patients with metastatic breast cancer | 2.2 | 55 | Citations (PDF) |
| 257 | Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer | 2.4 | 78 | Citations (PDF) |
| 258 | Serum HER2 levels determined by two methods in patients with metastatic breast cancer | 2.4 | 8 | Citations (PDF) |
| 259 | Information Sharing and Case Conference Among the Multidisciplinary Team Improve Patients’ Perceptions of Care | 0.4 | 14 | Citations (PDF) |
| 260 | Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis | 2.7 | 17 | Citations (PDF) |
| 261 | Inflammatory Breast Cancer: The Disease, the Biology, the Treatment | 169.1 | 294 | Citations (PDF) |
| 262 | Targeted therapy in inflammatory breast cancer | 4.4 | 10 | Citations (PDF) |
| 263 | Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions | 0.7 | 38 | Citations (PDF) |
| 264 | Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer | 1.5 | 29 | Citations (PDF) |
| 265 | PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase | 6.4 | 39 | Citations (PDF) |
| 266 | <sup>18</sup>F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer | 6.6 | 52 | Citations (PDF) |
| 267 | Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer | 1.7 | 18 | Citations (PDF) |
| 268 | ABC conceptual model of effective multidisciplinary cancer care | 25.3 | 17 | Citations (PDF) |
| 269 | Is High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal? | 1.6 | 4 | Citations (PDF) |
| 270 | Future directions of bone-targeted therapy for metastatic breast cancer | 25.3 | 89 | Citations (PDF) |
| 271 | Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer | 2.5 | 55 | Citations (PDF) |
| 272 | Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST | 2.7 | 201 | Citations (PDF) |
| 273 | Lapatinib in the Treatment of Breast Cancer | 0.1 | 0 | Citations (PDF) |
| 274 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer | 6.4 | 103 | Citations (PDF) |
| 275 | A novel hTERT promoter–driven E1A therapeutic for ovarian cancer | 1.7 | 32 | Citations (PDF) |
| 276 | Interleukin-2 and granulocyte–macrophage–colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer | 1.6 | 4 | Citations (PDF) |
| 277 | Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model | 4.0 | 46 | Citations (PDF) |
| 278 | Circulating Tumor Cells and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer | 17.1 | 125 | Citations (PDF) |
| 279 | Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in Perceived Importance Over Time | 1.5 | 36 | Citations (PDF) |
| 280 | Pilot Study of Targeted Skeletal Radiation Therapy for Bone-Only Metastatic Breast Cancer | 2.4 | 9 | Citations (PDF) |
| 281 | Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells | 5.0 | 66 | Citations (PDF) |
| 282 | Molecular targets for treatment of inflammatory breast cancer | 25.3 | 49 | Citations (PDF) |
| 283 | Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis | 21.9 | 152 | Citations (PDF) |
| 284 | Prognostic value of nodal ratios in node-positive breast cancer: a compiled update | 2.4 | 49 | Citations (PDF) |
| 285 | The Medical Treatment of Inflammatory Breast Cancer | 1.9 | 32 | Citations (PDF) |
| 286 | PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival | 0.6 | 61 | Citations (PDF) |
| 287 | Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells | 1.7 | 72 | Citations (PDF) |
| 288 | Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience | 4.3 | 117 | Citations (PDF) |
| 289 | Stem Cell Transplantation for Metastatic and High-Risk Nonmetastatic Breast Cancer: A Novel Treatment Approach 2008, , 387-410 | | 0 | Citations (PDF) |
| 290 | Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers | 0.0 | 26 | Citations (PDF) |
| 291 | Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed ImmunotherapyBlood, 2008, 112, 5440-5440 | 1.0 | 1 | Citations (PDF) |
| 292 | Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt | 0.6 | 99 | Citations (PDF) |
| 293 | Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity | 1.7 | 65 | Citations (PDF) |
| 294 | Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy | 1.7 | 22 | Citations (PDF) |
| 295 | What’s Past Is Prologue: Lessons Learned and the Need for Further Development of Allogeneic Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma | 1.5 | 10 | Citations (PDF) |
| 296 | Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation | 1.5 | 3 | Citations (PDF) |
| 297 | Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells | 5.0 | 5 | Citations (PDF) |
| 298 | Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden | 2.4 | 133 | Citations (PDF) |
| 299 | Inflammatory breast cancer (IBC) and patterns of recurrence | 4.4 | 177 | Citations (PDF) |
| 300 | Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.Blood, 2007, 110, 620-620 | 1.0 | 5 | Citations (PDF) |
| 301 | Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies. | 1.0 | 0 | Citations (PDF) |
| 302 | Trials and Tribulations in Developing Clinical Trials of Gene Therapy 2007, , 387-398 | | 0 | Citations (PDF) |
| 303 | Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer | 17.1 | 166 | Citations (PDF) |
| 304 | In Reply: | 17.1 | 0 | Citations (PDF) |
| 305 | Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model | 0.6 | 26 | Citations (PDF) |
| 306 | Cyclin A–associated kinase activity is needed for paclitaxel sensitivity | 1.7 | 16 | Citations (PDF) |
| 307 | Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint | 0.6 | 214 | Citations (PDF) |
| 308 | Graft—Versus—Breast Cancer Effect by Allogeneic Hematopoietic Stem-Cell Transplantation: A Possible New Frontier | 17.1 | 2 | Citations (PDF) |
| 309 | Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylenimine | 11.3 | 129 | Citations (PDF) |
| 310 | Bone Imaging in Metastatic Breast Cancer | 17.1 | 530 | Citations (PDF) |
| 311 | The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy | 1.5 | 22 | Citations (PDF) |
| 312 | Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection | 1.5 | 6 | Citations (PDF) |
| 313 | Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumorsBlood, 2003, 102, 3829-3836 | 1.0 | 129 | Citations (PDF) |
| 314 | Successful non‐myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome | 2.7 | 61 | Citations (PDF) |
| 315 | Cationic Liposome-Mediated<i>E1A</i>Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial | 17.1 | 184 | Citations (PDF) |
| 316 | Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation | 1.0 | 526 | Citations (PDF) |
| 317 | E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy | 2.2 | 20 | Citations (PDF) |
| 318 | Fatal Salmonella
group G
enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient | 2.2 | 4 | Citations (PDF) |
| 319 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia | 6.3 | 23 | Citations (PDF) |
| 320 | High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends | 2.4 | 6 | Citations (PDF) |
| 321 | ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY | 2.4 | 44 | Citations (PDF) |
| 322 | Primary malignant teratoma of the thyroid gland: Report and discussion of two cases 1998, 20, 649-653 | | 11 | Citations (PDF) |
| 323 | Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A | 6.6 | 80 | Citations (PDF) |
| 324 | Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center | 2.3 | 218 | Citations (PDF) |
